EUPRAXIA PHARMACEUTICALS INC.
EPRX$428M
Small CapNASDAQBiotechnology🇺🇸North America33 employees
Drugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
EPRX News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EP-104IAR 25 mg | Phase 2 | Osteoarthritis, Knee | - | - |
EP-104GI | Phase 2 | Eosinophilic Esophagitis | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply